arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 7/2019 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    NEW ON THE MARKET

    Dapagliflozin (FORXIGA): first oral antidiabetic for type 1 diabetes

    Risankizumab (SKYRIZI) for psoriasis

    THERAPY FROM A CRITICAL VIEWPOINT

    COMPASS trial: pantoprazole safe, but without benefit

    a-t READERS QUESTIONS AND COMMENTS

    High dose statin for coronary heart disease?

    Methotrexate (LANTAREL, generics) for rheumatoid arthritis or psoriasis … prefer subcutaneous over oral application?

    IN BRIEF

    Platelet aggregation inhibitors after cerebral haemorrhage – yes or no?

    CURRENT ADR NETWORK REPORT

    Generalized pruritus due to empagliflozin (JARDIANCE)
    free

    SIDE EFFECTS

    Caution: increased mortality with the gout medication febuxostat (ADENURIC)

    EMA: long-lasting sexual adverse effects due to SSRI and SNRI

    e a-t ON THE INTERNET

    Risankizumab (SKYRIZI) for psoriasis (long version)

    Tocilizumab (ROACTEMRA): severe liver damage

    EMA: long-lasting sexual adverse effects due to SSRI and SNRI (long version)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles